Klin Monbl Augenheilkd 2019; 236(04): 578-580
DOI: 10.1055/a-0800-8066
Der interessante Fall
Georg Thieme Verlag KG Stuttgart · New York

Regression of Optic Disc Neovascularization (NVD) in a Patient with Behçetʼs Disease Treated with Oral Corticosteroids and Adalimumab (ADA)

Regression der Papillenneovaskularisation (NVD) bei einem Patienten mit Behçet-Krankheit unter Behandlung mit oralen Kortikosteroiden und Adalimumab
Ioannis Papasavvas
1   Ophthalmology, RétinElysée, Lausanne, Switzerland
2   Ophthalmology, Clinique de Montchoisi, Centre C, Lausanne, Switzerland
,
Aude Ambresin
1   Ophthalmology, RétinElysée, Lausanne, Switzerland
,
Jean-Antoine Pournaras
1   Ophthalmology, RétinElysée, Lausanne, Switzerland
,
Laure Henchoz
3   Ophthalmology, Cabinet dʼOphtalmologie, Moudon, Switzerland
,
Jean Vaudaux
1   Ophthalmology, RétinElysée, Lausanne, Switzerland
4   Ophthalmology, Private practice, Morges, Switzerland
› Author Affiliations
Further Information

Publication History

received 19 September 2018

accepted 08 November 2018

Publication Date:
07 January 2019 (online)

Background

Optic disc and retinal neovascularization are uncommon but severe complications of Behçetʼs disease, which, as a result of occlusive retinal vasculitis, may lead to visual impairment and lacks standardized treatment.

 
  • References

  • 1 Dick AD, Rosenbaum JT, Al-Dhibi HA. et al. Guidance on noncorticosteroid systemic immunomodulatory therapy in noninfectious uveitis. Fundamentals of Care for UveitiS (FOCUS) initiative. Ophthalmology 2018; 125: 757-773
  • 2 Ming S, Xie K, He H. et al. Efficacy and safety of adalimumab in the treatment of non-infectious uveitis: a meta-analysis and systematic review. Drug Des Devel Ther 2018; 12: 2005-2016
  • 3 Tugal-Tutkun I, Onal S, Altan-Yaycioglu R. et al. Neovascularization of the optic disc in Behçetʼs disease. Jpn J Ophthalmol 2006; 50: 256-265
  • 4 Kawaguchi T, Sugita S, Yamada Y. et al. Regression of optic disc neovascularization in patients with Behçetʼs uveoretinitis after infliximab therapy. J Ocul Pharmacol Ther 2010; 26: 627-630